No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	idelalisib Sensitive: A1 - Approval idelalisib Sensitive : A1	idelalisib Sensitive: A1 - Approval idelalisib Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	duvelisib Sensitive: A1 - Approval duvelisib Sensitive : A1	duvelisib Sensitive: A1 - Approval duvelisib Sensitive : A1
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	rituximab + idelalisib Sensitive: A1 - Approval rituximab + idelalisib Sensitive : A1	rituximab + idelalisib Sensitive: A1 - Approval rituximab + idelalisib Sensitive : A1
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	rituximab + idelalisib Sensitive: A1 - Approval rituximab + idelalisib Sensitive : A1	rituximab + idelalisib Sensitive: A1 - Approval rituximab + idelalisib Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	copanlisib Sensitive: A1 - Approval copanlisib Sensitive : A1	copanlisib Sensitive: A1 - Approval copanlisib Sensitive : A1
No biomarker	Small Lymphocytic Lymphoma	No biomarker	Small Lymphocytic Lymphoma	duvelisib Sensitive: A1 - Approval duvelisib Sensitive : A1	duvelisib Sensitive: A1 - Approval duvelisib Sensitive : A1
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	idelalisib + ofatumumab Sensitive: A1 - Approval idelalisib + ofatumumab Sensitive : A1	idelalisib + ofatumumab Sensitive: A1 - Approval idelalisib + ofatumumab Sensitive : A1
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	idelalisib + ofatumumab Sensitive: A1 - Approval idelalisib + ofatumumab Sensitive : A1	idelalisib + ofatumumab Sensitive: A1 - Approval idelalisib + ofatumumab Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	rituximab + idelalisib Sensitive: A1 - Approval rituximab + idelalisib Sensitive : A1	rituximab + idelalisib Sensitive: A1 - Approval rituximab + idelalisib Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	umbralisib Sensitive: A1 - Approval umbralisib Sensitive : A1	umbralisib Sensitive: A1 - Approval umbralisib Sensitive : A1
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	umbralisib Sensitive: A1 - Approval umbralisib Sensitive : A1	umbralisib Sensitive: A1 - Approval umbralisib Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	duvelisib Sensitive: A1 - Approval duvelisib Sensitive : A1	duvelisib Sensitive: A1 - Approval duvelisib Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	rituximab + idelalisib Sensitive: A2 - Guideline rituximab + idelalisib Sensitive : A2	rituximab + idelalisib Sensitive: A2 - Guideline rituximab + idelalisib Sensitive : A2
No biomarker	Small Lymphocytic Lymphoma	No biomarker	Small Lymphocytic Lymphoma	rituximab + idelalisib Sensitive: A2 - Guideline rituximab + idelalisib Sensitive : A2	rituximab + idelalisib Sensitive: A2 - Guideline rituximab + idelalisib Sensitive : A2
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2
Chr del(17p)	Small Lymphocytic Lymphoma	Chr del(17p)	Small Lymphocytic Lymphoma	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2
Chr del(17p)	Small Lymphocytic Lymphoma	Chr del(17p)	Small Lymphocytic Lymphoma	rituximab + idelalisib Sensitive: A2 - Guideline rituximab + idelalisib Sensitive : A2	rituximab + idelalisib Sensitive: A2 - Guideline rituximab + idelalisib Sensitive : A2
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	rituximab + idelalisib Sensitive: A2 - Guideline rituximab + idelalisib Sensitive : A2	rituximab + idelalisib Sensitive: A2 - Guideline rituximab + idelalisib Sensitive : A2
Chr del(17p)	Small Lymphocytic Lymphoma	Chr del(17p)	Small Lymphocytic Lymphoma	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2
No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	copanlisib Sensitive: A2 - Guideline copanlisib Sensitive : A2	copanlisib Sensitive: A2 - Guideline copanlisib Sensitive : A2
No biomarker	Small Lymphocytic Lymphoma	No biomarker	Small Lymphocytic Lymphoma	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2
TP53 wild-type	Small Lymphocytic Lymphoma	TP53 wild-type	Small Lymphocytic Lymphoma	rituximab + idelalisib Sensitive: A2 - Guideline rituximab + idelalisib Sensitive : A2	rituximab + idelalisib Sensitive: A2 - Guideline rituximab + idelalisib Sensitive : A2
TP53 deletion	Chronic Lymphocytic Leukemia	TP53 deletion	Chronic Lymphocytic Leukemia	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2	idelalisib Sensitive: A2 - Guideline idelalisib Sensitive : A2
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2	duvelisib Sensitive: A2 - Guideline duvelisib Sensitive : A2
No biomarker	Small Lymphocytic Lymphoma	No biomarker	Small Lymphocytic Lymphoma	BR + idelalisib Sensitive: A2 - Guideline BR + idelalisib Sensitive : A2	BR + idelalisib Sensitive: A2 - Guideline BR + idelalisib Sensitive : A2

PI3Kδ inhibitor

PI3Kδ inhibitor

Associations(107)

Associations
(107)